Check patentability & draft patents in minutes with Patsnap Eureka AI!

Selective androgen receptor degrader (SARD) ligands and methods of use thereof

An androgen receptor, selective technology, applied in and including the field of heterocycles, can solve the problem of non-existent improvement of disease treatment

Pending Publication Date: 2021-07-23
UNIV OF TENNESSEE RES FOUND
View PDF16 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, no disease-modifying treatments exist, only symptom-directed treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Selective androgen receptor degrader (SARD) ligands and methods of use thereof
  • Selective androgen receptor degrader (SARD) ligands and methods of use thereof
  • Selective androgen receptor degrader (SARD) ligands and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0670] Synthesis of SARD

[0671] Synthesis of intermediates 9-10

[0672]

[0673] Scheme 1. Synthesis of intermediates 9-10.

[0674] (2R)-1-Methacryloylpyrrolidine-2-carboxylic acid (2)

[0675] D-Proline (1, 14.93 g, 0.13 mol) was dissolved in 71 mL of 2N NaOH and cooled in an ice bath. The resulting basic solution was diluted with acetone (71 mL). A solution of methacryloyl chloride (13.56 g, 0.13 mol) in acetone (71 mL) and 2N NaOH solution (71 mL) were added simultaneously to the aqueous solution of D-proline in an ice bath over 40 minutes. The temperature of the mixture was maintained at 10-11 °C during the addition of methacryloyl chloride. After stirring (3 hours (h), room temperature (RT)), the mixture was evaporated in vacuo at a temperature of 35-45 °C to remove acetone. The resulting solution was washed with ether and acidified to pH 2 with concentrated HCl. The acidic mixture was saturated with NaCl and extracted with EtOAc (100 mL x 3). The comb...

example 2

[0693] Androgen receptor binding, transactivation, degradation and metabolism of pyrazole, indole, benzotriazole and indazole SARDs

[0694] Ligand binding assay

[0695] Objective: To determine the binding affinity between SARD and AR-LBD.

[0696] Methods: The hAR-LBD(633-919) was cloned into pGex4t.1. Large-scale GST-tagged AR-LBD was prepared and purified using a GST column. Recombinant AR-LBD with [ 3 H] Mibolerone (PerkinElmer, Waltham, MA) was combined in buffer A (10 mM Tris, pH 7.4, 1.5 mM edetate disodium, 0.25 M sucrose, 10 mM sodium molybdate, 1 mM PMSF) to determine [ 3 H] The equilibrium dissociation constant (K d ). Proteins with and without high concentrations of unlabeled mibolone with increasing concentrations of [ 3 H] mibolerone were incubated together for 18 hours at 4°C in order to determine total and non-specific binding. Non-specific binding is then subtracted from total binding to determine specific binding and non-linear regression of the ligan...

example 3

[0731]

[0732] Synthesis of 3,5-difluoro-1H-indole

[0733] To a 50 mL round bottle flask with a magnetic stir bar add (872mg, 2.0mmol, 2.0eq), Li 2 CO 3 (296 mg, 4.0 mmol, 4.0 equiv), dichloromethane (3.3 mL) and water (1.7 mL). Carboxylic acid (1.0 mmol, 1.0 equiv) was then added. The reaction mixture was stirred in an ice bath for 2 hours. The reaction mixture was diluted with water (40 mL), then extracted with DCM (20 mL×2). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by flash column chromatography (n-Hexane:DCM=2:1) ​​to give 3,5-difluoro-1H-indole as dark brown oil. Yield = 68%;

[0734] MS(ESI)m / z 154.83[M+H] + ;152.03[M-H] - ;

[0735] 1 H NMR (CDCl 3 ,400MHz)δ7.86(bs,1H,NH),7.25(dd,J=9.2,2.4Hz,1H),7.20-7.16(m,1H),6.97(t,J=2.6Hz,1H),6.93 (dd,J=9.2,2.4Hz,1H);

[0736] 19 F NMR (CDCl 3 )δ-123.99(d,J F-F =2.8Hz), -174.74(d, J F-F = 4.0Hz).

[073...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Description

technical field [0001] The present invention relates to selective androgen receptor degrading agent (SARD) compounds and pharmaceutical compositions comprising heterocycles and their usefulness in the treatment of prostate cancer, advanced prostate cancer, castration-resistant prostate cancer, triple-negative breast cancer, androgen receptor-expressing other cancers in the body, androgenetic alopecia or other androgen excess skin disorders, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids Use, and relates to reducing the level of androgen receptor-full length (AR-FL) in individuals, including pathogenic and / or drug resistance mutations of AR, AR-splice variants (AR-SV) and pathogenic polyglutamine (polyQ) polymorphism method. Background technique [0002] Prostate cancer (PCa) is one of the most frequently diagnosed non-skin cancers in American men and the second most common cause of cancer death, with more than 2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/277A61K31/167A61K31/404A61P35/00A61P35/04
CPCA61P35/00A61P35/04C07D209/30C07D209/08C07D249/18C07D231/16C07D257/04C07D231/18C07D231/12C07D303/46C07D231/14C07D249/06C07D213/84C07C255/60A61K31/404A61K9/0014A61K31/277A61K31/336A61K31/4155A61K31/416A61K31/4192A61K31/4439A61K45/06C07D231/56A61P5/24A61P17/08A61P17/10A61P17/14
Inventor R·纳拉亚南D·D·米勒T·普努萨米D-J·黄Y·何
Owner UNIV OF TENNESSEE RES FOUND
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More